# E-nitiate Biopharmaceuticals (Hangzhou) Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/e-nitiate-biopharmaceuticals-hangzhou-co

- Industry: Biotechnology
- Headquarters: Hangzhou, China
- Website: www.enitiatebio.com
- Total disclosed funding: $43M
- Latest round: Series B (Sep 3, 2025)
- Investors on record: 8

## About

Established in 2020 and based in Hangzhou, China, E-nitiate Biopharmaceuticals (Hangzhou) Co.,Ltd operates as an autoimmune disease drug developer. The company was established by VivaVision Biotech and Betta Pharmaceuticals fund. Betta Pharmaceuticals has become the strategic partner of the company in December 2020. More than 70% employees of the core research team has master's or doctor's degree. Wang Shen is the CTO of the company, he is the founder of Weimou biology and inventor of Lifitegrast. Shizhe Ding is the CEO of the company, he is the co-founder of Bega Capital, and once served as the director of strategic cooperation of Beida pharmaceutical and executive deputy general manager of Beida dream factory.

The business of company includes R & D of innovative drugs for dermatology and immune diseases. The company's products include QY201 and QY101. QY201 can apply in psoriasis (moderate to severe), atopic dermatitis and alopecia areata. The company will submit for IND applications about QY211 and QY301.

## Funding rounds

- Series B, Sep 3, 2025, $28M — HighLight Capital, Fuzhe Capital, Guoshun Investment
- Series A, Aug 31, 2022, $15M — HFI Industry Fund Management, Shijie Investment, Taikun Fund, Linping SDIC
- Angel, Jun 30, 2021 — Beida Fund

## Investors

- Beida Fund (https://capitalatlas.ai/funds/beida-fund) — Angel
- HFI Industry Fund Management (https://capitalatlas.ai/funds/hfi-industry-fund-management) — Series A
- Shijie Investment (https://capitalatlas.ai/funds/shijie-investment) — Series A
- Taikun Fund — Series A
- Linping SDIC — Series A
- HighLight Capital (https://capitalatlas.ai/funds/highlight-capital) — Series B
- Fuzhe Capital (https://capitalatlas.ai/funds/fuzhe-capital) — Series B
- Guoshun Investment (https://capitalatlas.ai/funds/guoshun-investment) — Series B